Partnerships

GlaxoSmithKline Immuno-Oncology Financial Collaboration
Our immuno-oncology financial collaboration with GlaxoSmithKline (GSK) is focused upon the development and commercialization of Anaptys-generated checkpoint antagonist antibodies to PD-1 and TIM-3. The exclusively licensed products being advanced by GSK under this partnership include Jemperli™ (dostarlimab) and cobolimab in second line NSCLC.
Potential royalties from GSK immuno-oncology financial collaboration

Royalties

(Anti-PD-1 antagonist)

8% – 25% royalties on annual net sales

Cobolimab(Anti-TIM-3 antagonist)
  • Royalty rate on cobolimab includes potential cobolimab-portion of combination use with dostarlimab in P3 COSTAR trial (2L NSCLC)
  • 4-8% royalties on annual net sales

Remaining Milestones

(Anti-PD-1 antagonist)

$15mm regulatory
$90MM commercial on annual net sales <$1B

  • $75mm commercial on annual net sales ≥ $1B
Cobolimab(Anti-TIM-3 antagonist)
  • $5MM clinical development
  • $90MM regulatory
  • $165MM commercial

  • Jemperli Capped Non-Recourse Monetization:
  • Selected receivables (designated in orange text above) payable to Sagard until either of the following capped returns achieved:
  • $600MM by March 31, 2031
  • -or-
  • $675MM after March 31, 2031

Note: Anaptys’ capped non-recourse monetization agreement has brought a total of $300 million of non-dilutive capital, including $250 million in Oct. 2021 and $50 million in May 2024.
Note: Sale of Zejula (niraparib) royalty interest in September 2022 to wholly-owned subsidiary of DRI Healthcare Trust for $35mm upfront + $10mm potential milestone upon FDA approval of Zejula for the treatment of endometrial cancer, to the extent that such approval occurs on or before 12/31/25. At present, the Jemperli plus Zejula combination demonstrated significantly improved PFS in primary advanced or recurrent endometrial cancer in the RUBY Phase III trial.
Exclusive Global License Agreement with Vanda Pharmaceuticals for Imsidolimab (IL-36R)
Imsidolimab is an IgG4 antibody that inhibits the function of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of inflammatory diseases, including GPP

In February 2025, announced an exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist

Access scientific publications on our immuno-oncology and imsidolimab partnerships.